I’ve heard it said that most people have more to gain by leaning into their strengths than by working on their weaknesses. I’m not convinced that this is the case for companies raising venture dollars. Most VCs will look for the “deal killer”, the issue with your company that.

Quick discussion on @BiotechTV on a key dilemma for biotech: how can we make our industry interesting and accessible to the general population? @daphnezohar, @KendalleOC, and @bradloncar discuss this topic eloquently. They touch on several ways to tackle this challenge: 1).

RT @blakeaburge: The happiest people I know don't have perfect lives. But they have one thing in common: They've mastered the art of moving….

While biotech entrepreneurs are finding the fundraising environment challenging, the situation is even tougher for VCs trying to raise new funds. (Which is part of the reason that financings have slowed.) With slower IPO and M&A activity, and weak XBI performance over the past.

It’s August: the market is super-slow and many investors are out of the office. As an entrepreneur trying to raise capital, what can you do to set yourself up for a productive September? If your calendar is light, it could be a good time to refine your messaging as well as to.

RT @cngarabedian: Listen to Episode 24 of @BioVentureVoiCe video podcast w/ Srini Akkaraju of @samsaracapital and hear how his early involv….

Q for management teams: do you prefer direct outreach from potential new investors, or do you prefer to get a “warm intro” from an existing investor, board member, etc.? Many VCs lean toward going through an existing investor, director, advisor, etc. when possible – this serves a.

RT @LifeSciVC: Big late stage win for Takeda! . Oveporexton (TAK-861) hits on all endpoints in narcolepsy for the first-in-class orexin re….

In this challenging fundraising market, some companies are taking the somewhat unusual tactic of connecting interested firms with one another ahead of a term sheet. This approach has its pros and cons but is worth exploring in a market like the current one, characterized by a.

We’re in an incredibly challenging time for biotech fundraising. Endpoints reported on July 3 that megarounds ($100M+) were down 38% in 1H25 vs. the year prior, and that Q2’25 was tracking to be the slowest quarter for private biotech fundraising in over seven years. This also.

RT @daphnezohar: URGENT call to action: please contact any Republican senator you know to keep ORPHAN Cures Act & Accelerating Access for K….

RT @AdamMGrant: Dads are spending 3-4x as much time with their kids as their dads did with them. When father figures are engaged, kids sho….

RT @cngarabedian: Listen to Episode 21 of @BioVentureVoiCe video podcast w/ Aaron Kantoff of Scion Life Sciences and hear about his early….

RT @cngarabedian: Listen to Episode 18 of @BioVentureVoiCe video podcast w/ Jory Bell of @Playground_VC and hear about how he is applying P….

RT @daphnezohar: Cantor has put out some really interesting notes lately. Dueling takes from Eric Schmidt & Josh Schimmer on short selling….

RT @LifeSciVC: There's lots of noise about how the changes at the FDA are having a negative impact on biotech as a sector. FDA departures m….

RT @cngarabedian: Listen to Episode 17 of @BioVentureVoiCe video podcast w/ Tiba Aynechi of @NorwestVP and hear about how she is applying….

When deciding which team members to bring to a pitch, consider who will do the talking. Many times the presentation is done by only one or two people, and others are present simply to answer questions. This may not be the most efficient use of your team’s time, especially for a.

I was asked, “how bad is the market now compared to prior downturns?” While it’s easy to check on how public indices are doing, it’s harder to gauge real-time impact on the private market. Reports on VC activity are put out periodically by HSBC, SVB, and others – but those will.

RT @BiotechTVHQ: 𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰: Tune in tomorrow for a new episode of Off-Target Effects with @gline. Matt interviews Avoro Capital's Behzad Agh….